Condella Sarah 4

What Happened

• Sarah Condella, Executive VP of Human Resources at Exact Sciences (EXAS), had a mix of equity actions on March 23, 2026 tied to the company’s merger with Abbott. She was credited with 60,389 restricted stock units (RSUs) at $0.00 (an award/assumption), and a total of 269,502 EXAS shares/equity awards were surrendered/cancelled to the issuer as part of the merger consideration.
• Under the merger terms, outstanding common shares and certain awards were converted into the right to receive $105.00 per EXAS share (the “Merger Consideration”), and performance awards were treated as vested and converted to cash. Based on the $105 per-share merger consideration, the surrendered 269,502 shares/equivalents imply roughly $28.3 million in aggregate consideration (actual cash received can vary for options under conversion formulas and after tax withholding).

Key Details

• Transaction date: March 23, 2026 (Effective Time of the merger).
• Transactions recorded: Award/acquisition of 60,389 RSUs (@ $0.00) and dispositions to the issuer totaling 269,502 shares/equivalents (various equity types, many listed as derivative dispositions).
• Price/consideration: Merger Consideration = $105.00 per EXAS share (per Merger Agreement). Filing shows N/A prices for dispositions because awards/options were converted/cancelled under merger terms.
• Shares owned after transaction: 60,389 RSUs (assumed/converted by Parent as Parent RSUs per the merger filing).
• Notable footnotes: PSUs outstanding were deemed vested and converted to cash at $105.00 each; many RSUs granted on/after Nov 19, 2025 were assumed by Abbott as Parent RSUs on substantially similar terms; some awards retain multi-year vesting (e.g., certain RSUs vest in four equal annual installments beginning Feb 25, 2027).
• Filing timeliness: Report filed with a March 23, 2026 filing date for transactions effective the same day (no late filing indicated).

Context

• This activity is driven by the corporate merger (Exact Sciences was merged into an Abbott subsidiary) and reflects scheme-of-merger conversions and cancellations, not open-market selling or a typical executive sale. Derivative dispositions here mean awards (PSUs, RSUs, or options) were cancelled/converted under the merger rules—PSUs were cashed out, options were converted to cash if in-the-money, and certain RSUs were assumed by the acquirer as Parent RSUs.
• For retail investors: these entries reflect merger mechanics and payout/assumption of awards, not a trading decision by the insider about the company’s future prospects.